Open AccessTROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer
Author(s) -
Xiaoyue Liu,
Tianhao Zhou,
Yongmei Wang,
Min Pei,
Guifeng Wang,
Wendi Chu,
Qi Wang,
Shaoqian Du,
Hongxia Wang,
Chunhe Wang
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s354048
Subject(s) - medicine , biomarker , tissue microarray , breast cancer , immunohistochemistry , triple negative breast cancer , cancer research , oncology , mesothelin , antibody drug conjugate , cancer , antibody , immunology , monoclonal antibody , biology , biochemistry
Trophoblast cell surface antigen 2 (TROP2) has emerged as a promising target of antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC), as well as other breast cancers (BCs). This study aims to investigate the biomarker value of TROP2 for patient-tailoring and prognostic for BC patients, including TNBC.